RU2489443C2 - Изобретение, относящееся к glp-1 и эксендинам - Google Patents

Изобретение, относящееся к glp-1 и эксендинам Download PDF

Info

Publication number
RU2489443C2
RU2489443C2 RU2010148447/10A RU2010148447A RU2489443C2 RU 2489443 C2 RU2489443 C2 RU 2489443C2 RU 2010148447/10 A RU2010148447/10 A RU 2010148447/10A RU 2010148447 A RU2010148447 A RU 2010148447A RU 2489443 C2 RU2489443 C2 RU 2489443C2
Authority
RU
Russia
Prior art keywords
exendin
glp
derivatives
peptides
agent
Prior art date
Application number
RU2010148447/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2010148447A (ru
Inventor
Мартин ГОТТХАРДТ
Мартин БЭЭ
Томас Бер
Буркхард Й. ГЕКЕ
Original Assignee
Филиппс-Универзитет Марбург
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Филиппс-Универзитет Марбург filed Critical Филиппс-Универзитет Марбург
Publication of RU2010148447A publication Critical patent/RU2010148447A/ru
Application granted granted Critical
Publication of RU2489443C2 publication Critical patent/RU2489443C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
RU2010148447/10A 2004-09-03 2005-08-26 Изобретение, относящееся к glp-1 и эксендинам RU2489443C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004043153.1 2004-09-03
DE102004043153A DE102004043153B4 (de) 2004-09-03 2004-09-03 Erfindung betreffend GLP-1 und Exendin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2007112115/10A Division RU2420536C2 (ru) 2004-09-03 2005-08-26 Пептидные производные эксендина-4

Publications (2)

Publication Number Publication Date
RU2010148447A RU2010148447A (ru) 2012-06-10
RU2489443C2 true RU2489443C2 (ru) 2013-08-10

Family

ID=35970651

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2010148447/10A RU2489443C2 (ru) 2004-09-03 2005-08-26 Изобретение, относящееся к glp-1 и эксендинам
RU2007112115/10A RU2420536C2 (ru) 2004-09-03 2005-08-26 Пептидные производные эксендина-4
RU2010148446/10A RU2486197C2 (ru) 2004-09-03 2010-11-26 Изобретение, относящееся к glp-1 и эксендинам

Family Applications After (2)

Application Number Title Priority Date Filing Date
RU2007112115/10A RU2420536C2 (ru) 2004-09-03 2005-08-26 Пептидные производные эксендина-4
RU2010148446/10A RU2486197C2 (ru) 2004-09-03 2010-11-26 Изобретение, относящееся к glp-1 и эксендинам

Country Status (16)

Country Link
US (2) US8268781B2 (enExample)
EP (3) EP2301962B1 (enExample)
JP (1) JP5047795B2 (enExample)
KR (1) KR101237152B1 (enExample)
CN (3) CN102358752B (enExample)
AT (1) ATE486090T1 (enExample)
AU (1) AU2005279537C1 (enExample)
BR (1) BRPI0515624A (enExample)
CA (2) CA2578252A1 (enExample)
DE (2) DE102004043153B4 (enExample)
HR (1) HRP20110061T1 (enExample)
MX (1) MX2007002455A (enExample)
NO (1) NO20071592L (enExample)
PL (2) PL2070946T3 (enExample)
RU (3) RU2489443C2 (enExample)
WO (1) WO2006024275A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007017892A2 (en) * 2005-05-05 2007-02-15 Cadila Healthcare Limited Novel compounds as glp-i agonists
EP3456340B1 (en) 2007-01-08 2022-02-16 The Trustees of the University of Pennsylvania Glp-1 receptor antagonist for use in the treatment of congenital hyperinsulinism
JP4642920B2 (ja) * 2008-09-20 2011-03-02 国立大学法人京都大学 膵島イメージング用分子プローブ前駆体及びその使用
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
WO2010118034A2 (en) * 2009-04-06 2010-10-14 Board Of Regents, The University Of Texas System Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
WO2011019020A1 (ja) * 2009-08-10 2011-02-17 国立大学法人京都大学 膵島イメージング用分子プローブ及びその前駆体、並びに、それらの使用
WO2011027584A1 (ja) * 2009-09-04 2011-03-10 国立大学法人京都大学 膵島イメージング用分子プローブ及びその使用
JP5608867B2 (ja) * 2009-09-30 2014-10-15 国立大学法人京都大学 膵島イメージング用分子プローブ及びその使用
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
KR101550006B1 (ko) 2009-12-10 2015-09-03 아크레이 가부시키가이샤 췌도 이미징용 분자 프로브 및 그 사용
CN101875700B (zh) * 2010-04-09 2012-09-26 无锡和邦生物科技有限公司 一种增加促胰岛素分泌肽融合蛋白生物活性的方法
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9278146B2 (en) 2010-10-08 2016-03-08 Kyoto University Peptide derivative and use of the same
WO2012121746A2 (en) * 2011-03-09 2012-09-13 The General Hospital Corporation Imaging beta cell mass
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US8901484B2 (en) * 2012-04-27 2014-12-02 Sanofi-Aventis Deutschland Gmbh Quantification of impurities for release testing of peptide products
WO2013182217A1 (en) * 2012-04-27 2013-12-12 Sanofi-Aventis Deutschland Gmbh Quantification of impurities for release testing of peptide products
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) * 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
CN103344764B (zh) * 2013-06-19 2014-11-26 天津美德太平洋科技有限公司 胰高血糖素样肽-1生物学活性检测试剂及检测方法和试剂盒
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
DE102014112747A1 (de) * 2014-09-04 2016-03-10 Eberhard Karls Universität Tübingen Medizinische Fakultät Verwendung eines Quinoxalinderivats in einem bildgebenden Verfahren
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
PL3297654T3 (pl) 2015-05-22 2021-12-20 The Board Of Trustees Of The Leland Stanford Junior University Leczenie pobariatrycznej hipoglikemii eksendyną (9-39)
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
SI3389697T1 (sl) 2015-12-14 2021-02-26 Antaros Medical Ab Selektivni agonisti receptorja glukagona, ki obsegajo kelatni del za namene prikazovanja
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
SMT202500120T1 (it) 2016-11-21 2025-05-12 Amylyx Pharmaceuticals Inc Formulazioni tamponate di esendina (9-39)
EP4171662A1 (en) 2020-03-31 2023-05-03 Antaros Medical AB Selective gip receptor agonists comprising a chelating moiety for imaging and therapy purposes

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE120374T1 (de) * 1989-07-20 1995-04-15 Sandoz Ag Markierte polypeptidderivate.
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
AU723694B2 (en) * 1996-06-05 2000-08-31 Roche Diagnostics Gmbh Exendin analogues, processes for their preparation and medicaments containing them
JP2002508162A (ja) * 1998-02-27 2002-03-19 ノボ ノルディスク アクティーゼルスカブ Ｎ末端を短縮したｇｌｐ−１誘導体
AU3247799A (en) * 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
US7259136B2 (en) * 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
EP1137667B1 (en) * 1998-12-07 2004-11-17 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogues of glp-1
BR0010705A (pt) * 1999-04-30 2002-02-05 Amylin Pharmaceuticals Inc Exendinas modificadas e agonistas da exendina
AU765753B2 (en) * 1999-05-17 2003-09-25 Conjuchem Biotechnologies Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
PT1180121E (pt) * 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
WO2001051078A1 (en) * 2000-01-10 2001-07-19 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US20030232761A1 (en) * 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
BR0314996A (pt) * 2002-10-02 2005-08-09 Zealand Pharma As Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
WO2004037859A1 (ja) * 2002-10-11 2004-05-06 Sanwa Kagaku Kenkyusho Co., Ltd. Glp-1誘導体及びその経粘膜吸収型製剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ENG J. et al. Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom. J. Biol. Chem. 1990, v.265, n.33, pp.20259-20262. RAUFMAN J.P. et al. Exendin-3, a novel peptide from Heloderma horridum venom, interacts with vasoactive intestinal peptide receptors and a newly described receptor on dispersed acini from guinea pig pancreas. Description of exendin-3(9-39) amide, a specific exendin receptor antagonist. J. Biol. Chem. 1991, v.266, n.5, pp.2897-2902. *

Also Published As

Publication number Publication date
PL2301962T3 (pl) 2014-05-30
WO2006024275A3 (de) 2006-11-30
KR20070093960A (ko) 2007-09-19
US20130095037A1 (en) 2013-04-18
EP2301962B1 (de) 2013-10-30
DE502005010449D1 (de) 2010-12-09
HRP20110061T1 (hr) 2011-02-28
US20090180953A1 (en) 2009-07-16
BRPI0515624A (pt) 2008-07-29
EP2070946A3 (de) 2009-09-09
EP2070946B1 (de) 2013-05-29
WO2006024275A2 (de) 2006-03-09
MX2007002455A (es) 2007-10-10
AU2005279537A1 (en) 2006-03-09
ATE486090T1 (de) 2010-11-15
RU2007112115A (ru) 2008-10-10
JP2008511557A (ja) 2008-04-17
US8268781B2 (en) 2012-09-18
KR101237152B1 (ko) 2013-03-04
JP5047795B2 (ja) 2012-10-10
RU2010148447A (ru) 2012-06-10
EP2301962A3 (de) 2011-11-02
AU2005279537C1 (en) 2012-07-05
RU2486197C2 (ru) 2013-06-27
RU2420536C2 (ru) 2011-06-10
RU2010148446A (ru) 2012-06-10
AU2005279537B2 (en) 2012-02-16
DE102004043153A1 (de) 2006-03-23
CN102358752A (zh) 2012-02-22
EP2070946A2 (de) 2009-06-17
DE102004043153B4 (de) 2013-11-21
CA2797666A1 (en) 2006-03-09
EP1784422A2 (de) 2007-05-16
CN101010340B (zh) 2012-11-28
CN101010340A (zh) 2007-08-01
CN102304179A (zh) 2012-01-04
NO20071592L (no) 2007-05-29
EP1784422B1 (de) 2010-10-27
CA2578252A1 (en) 2006-03-09
PL2070946T3 (pl) 2013-09-30
EP2301962A2 (de) 2011-03-30
CN102358752B (zh) 2014-07-30

Similar Documents

Publication Publication Date Title
RU2486197C2 (ru) Изобретение, относящееся к glp-1 и эксендинам
EP2454272B1 (en) Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors
Kimura et al. Synthesis and biological evaluation of an 111In-labeled exendin-4 derivative as a single-photon emission computed tomography probe for imaging pancreatic β-cells
Azad et al. Design, synthesis and in vitro characterization of Glucagon-Like Peptide-1 derivatives for pancreatic beta cell imaging by SPECT
US6855308B2 (en) PACAP compositions and methods for tumor imaging and therapy
JP2023520769A (ja) イメージング及び治療目的のキレート部分を含む選択的ｇｉｐ受容体アゴニスト
US6395255B1 (en) Radiolabeled vasoactive intestinal peptide analogs for imaging and therapy
JP4318985B2 (ja) ソマトスタチンアナログ誘導体およびその利用
JP2019508480A (ja) イメージング目的のためのキレート部分を含む選択的グルカゴン受容体アゴニスト
AU2012202855B2 (en) GLP-1 and exendin related invention
Vallabhajosula Theranostics in Neuroendocrine Tumors
JP2005538966A (ja) 金属錯体形成により環化した標識ソマトスタチン同族体骨格
Chandra et al. Synthesis, radiolabeling and biological evaluation of a neutral tripeptide and its derivatives for potential nuclear medicine applications

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20130827

NF4A Reinstatement of patent

Effective date: 20140920

MM4A The patent is invalid due to non-payment of fees

Effective date: 20170827